Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster
Sabrina Lusvarghi, Simon Pollett, Sabari Nath Neerukonda, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review
Santenna Chenchula, Padmavathi Karunakaran, Sushil Sharma, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 7, pp. 2969-2976
Open Access | Times Cited: 294
SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity
Stefan Pilz, Verena Theiler‐Schwetz, Christian Trummer, et al.
Environmental Research (2022) Vol. 209, pp. 112911-112911
Open Access | Times Cited: 232
Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants
Frank Esper, Thamali M. Adhikari, Zheng Jin Tu, et al.
The Journal of Infectious Diseases (2022) Vol. 227, Iss. 3, pp. 344-352
Open Access | Times Cited: 116
Omicron (B.1.1.529) variant of SARS‐CoV‐2: Concerns, challenges, and recent updates
Ranjan K. Mohapatra, Ruchi Tiwari, Ashish K. Sarangi, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 6, pp. 2336-2342
Open Access | Times Cited: 82
Antiviral Drug Discovery for the Treatment of COVID-19 Infections
Teresa I. Ng, Ivan Correia, Jane Seagal, et al.
Viruses (2022) Vol. 14, Iss. 5, pp. 961-961
Open Access | Times Cited: 77
Covid-19: virology, variants, and vaccines
Megan Young, Harry Crook, J. T. Scott, et al.
BMJ Medicine (2022) Vol. 1, Iss. 1, pp. e000040-e000040
Open Access | Times Cited: 43
Recent insights into SARS‐CoV‐2 omicron variant
Severino Jefferson Ribeiro da Silva, Alain Kohl, Lindomar Pena, et al.
Reviews in Medical Virology (2022) Vol. 33, Iss. 1
Open Access | Times Cited: 43
Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium
Heather Callaway, Kathryn M. Hastie, Sharon L. Schendel, et al.
Cell Reports (2023) Vol. 42, Iss. 1, pp. 112014-112014
Open Access | Times Cited: 22
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 32
Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review
Zhonghao Chen, Ying Zhang, Meng Wang, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 12, pp. 4629-4641
Open Access | Times Cited: 30
Analysis of SARS-CoV-2 Omicron Neutralization Data up to 2022-01-28
Antonia Netzl, Sina Türeli, Eric B. LeGresley, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 29
Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review
Yuxuan Du, Long Chen, Yuan Shi
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 5
Open Access | Times Cited: 25
Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention
Ailan Xu, Bixia Hong, Fuxing Lou, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 25
A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant.
S.O Minka, F.-H. Minka
Immunology Letters (2022) Vol. 243, pp. 38-43
Open Access | Times Cited: 22
Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years
Enagnon Kazali Alidjinou, Julie Demaret, Bénédicte Corroyer-Simovic, et al.
The Lancet Regional Health - Europe (2022) Vol. 17, pp. 100385-100385
Open Access | Times Cited: 22
The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages
Tiandan Xiang, Junzhong Wang, Xin Zheng
Virologica Sinica (2022) Vol. 37, Iss. 6, pp. 786-795
Open Access | Times Cited: 21
Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination
Francesca Dapporto, Serena Marchi, Margherita Leonardi, et al.
Journal of Immunology Research (2022) Vol. 2022, pp. 1-9
Open Access | Times Cited: 20
Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19
Babafemi Taiwo, Kara W. Chew, Carlee Moser, et al.
The Journal of Infectious Diseases (2023) Vol. 228, Iss. 2, pp. 133-142
Open Access | Times Cited: 10
Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination
Nungruthai Suntronwong, Suvichada Assawakosri, Sitthichai Kanokudom, et al.
Diagnostics (2022) Vol. 12, Iss. 8, pp. 1781-1781
Open Access | Times Cited: 16
Imaging Severity COVID-19 Assessment in Vaccinated and Unvaccinated Patients: Comparison of the Different Variants in a High Volume Italian Reference Center
Vincenza Granata, Roberta Fusco, Alberta Villanacci, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 6, pp. 955-955
Open Access | Times Cited: 15
Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations
Claudia Maria Trombetta, Giulia Piccini, Giulio Pierleoni, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 13
Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants
Zhaochun Chen, Peng Zhang, Yumiko Matsuoka, et al.
Cell Reports (2022) Vol. 41, Iss. 5, pp. 111528-111528
Open Access | Times Cited: 13
Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination
Almir Ribeiro da Silva, Lucy Santos Villas-Boas, Tânia Regina Tozetto‐Mendoza, et al.
Revista do Instituto de Medicina Tropical de São Paulo (2022) Vol. 64
Open Access | Times Cited: 11
Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases
Caoilfhionn M Connolly, Teresa Po‐Yu Chiang, Mayan Teles, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 6, pp. e382-e384
Open Access | Times Cited: 10
Enhancing Immunological Memory: Unveiling Booster Doses to Bolster Vaccine Efficacy Against Evolving SARS-CoV-2 Mutant Variants
Sovan Samanta, Jhimli Banerjee, Aparna Das, et al.
Current Microbiology (2024) Vol. 81, Iss. 3
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top